Trial: 202005075

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard


II (Cancer Control)

Principal Investigator

Oh, Stephen

Disease Site

Other Hematopoietic

Learn more about this study at: